Introduction
Neuroblastoma is the most common solid tumor found in children and accounts for 7-10% of pediatric malignancies (Devary et al., 1992) . Unfortunately, less than 20% of high-grade neuroblastoma patients survive despite the currently available chemotherapeutic and radiation therapies (Frappaz et al., 2000; Schmidt et al., 2000) . Neuroblastoma is a heterogeneous tumor derived from primordial neural crest cells (Anderson, 1993) . Original in vitro cultures of neuroblastoma cells also gave a mixture of cell morphologies (Tumilowicz et al., 1970; Biedler et al., 1973) , and subsequent cloning revealed three distinct cell types (Ciccarone et al., 1989) . Neuronal (N) cells, including the neuroblastoma cell lines SH-SY5Y, SK-N-BE(2)-M17, SMS-KCN-62n and IMR32, show neurite-like processes with small, rounded cell bodies that tend to aggregate. N cells are loosely adherent to the substrate, show cell surface markers characteristic of neuronal precursors such as opioid, muscarinic and nerve growth factor receptors (Rettig et al., 1987) , grow in mitogen-free media and form tumors in nude mice (Biedler et al., 1988) . Nontumorigenic S (Schwannian or stromal) cells, including the SH-EP, LAI-5s, SK-N-BE(2)-7s, SMS-KCN-9s and SK-N-AS cell lines, are larger, highly adherent cells that grow flattened and express tyrosinase activity, synthesize fibronectin, vimentin and type IV collagens and cytoplasmic and cell surface proteins characteristic of glial or Schwann cell types (Ross and Biedler, 1985; DeClerck et al., 1987; Rettig et al., 1987) . The third type of cells, termed 'I' for 'intermediate', have biochemical characteristics of both cell lines and can be differentiated into exclusively N or S cells (Ross et al., 1995) .
As N and S cells arise from the same primary tumor, but have very different tumorigenic properties, identifying the factors that lead to differences between these two cell types will increase our understanding of how tumor cells progress to a malignant phenotype. Growing evidence suggests that growth factors, including the family of insulin-like growth factors, have potent effects on neuroblastoma tumorigenesis and are instrumental in defining the malignant phenotype (Yee, 2002; Brodeur, 2003) .
IGF signaling plays important roles in the malignant transformation of many tumors, including neuroblastoma (Baserga, 1995; Zumkeller and Schwab, 1999) , and circulating levels of IGF-I are increased in several common cancers (Chan et al., 1998; Hankinson et al., 1998; Yu et al., 1999) . Most of the physiological effects of IGFs are mediated by the type I IGF receptor (IGF-IR). Upon ligand binding of the IGF-IR, autophosphorylation of its b-subunits occurs, resulting in binding of the major IGF-IR substrates, insulin receptor substrate (IRS)-1, -2 and Shc (Pronk et al., 1993; Giorgetti et al., 1994; Myers and White, 1996) . The signaling pathways mediated by Shc and IRS proteins, including the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI 3-K) pathways, are implicated in the effects of IGF-I on cell survival, mitogenesis, differentiation and cytoskeletal changes (De Meyts et al., 1994; Cheatham and Kahn, 1995; Miller et al., 1997; Kim and Feldman, 1998; Kim et al., 1998a) . Targeted disruption of IGF-IR signaling by antisense mRNA or dominant-negative mutants results in inhibition of tumorigenesis in vivo and in vitro by allowing apoptosis to occur (Liu et al., 1998; Reiss et al., 1998) .
Our research focuses on the pleiotrophic effects of IGF-I signaling in human neuroblastoma Meyer and Feldman, 2002; Vincent and Feldman, 2002) . We have previously reported that IGF-I treatment of N cells induces morphological changes accompanied by actin cytoskeletal rearrangement Kim and Feldman, 1998; Kim et al., 1998a) followed by neuronal differentiation . IGF-I treatment also enhances the motility of N and S cells (Meyer et al., 2001) . In this report, we extended our previous studies with a more detailed examination of differential IGF-I signaling in N-and Stype neuroblastoma cell lines. We show that the more tumorigenic N cells express higher levels of IGF-IR than S cells. Shc expression is uniform in all cell lines tested. However, the expression of IRS-1 and -2 is cell type specific; N cells exclusively express IRS-2 and S cells IRS-1. Less adherent N cells express very low levels of paxillin and b1 integrin. N cells show higher levels of IGF-I-induced phosphorylation, including IRS-1/2 and Shc and their downstream effector molecules Akt and MAPK. IGF-I treatment enhances membrane ruffling through PI 3-K activation. During IGF-I-mediated morphological changes, focal adhesion kinase (FAK) and paxillin are also phosphorylated and in N cells are actively relocated to membrane ruffling and lamellipodial regions. Long-term IGF-I exposure results in neurite outgrowth in N cells and requires activation of both PI 3-K and MAPK pathways. This detailed understanding of the 'biochemical signature' of N and S cells provides the background needed to target and disrupt specific IGF signaling pathways in an attempt to develop more effective therapies. Figure 1 shows the morphology of the control, serumstarved neuroblastoma cell lines. As previously reported (Biedler et al., 1973; Ciccarone et al., 1989) , S cells (SH-EP and SK-N-AS) display flattened shapes with little or no processes. SH-EP cells show two populations with distinct morphologies. A smaller population of the cells (asterisks) is very large with a polygonal shape, while the majority of the cells are narrow and elongated with occasional short processes (arrowheads). SK-N-AS cells are very different from other neuroblastoma cell lines in that they form islands of rosettes with very tightly adhering cells. Two N cell lines, SH-SY5Y and IMR32, are very similar in morphology. Their cell bodies are smaller than S cells and display long, branched neurites (arrows); IMR32 cells have longer neurites than SH-SY5Y cells. It is easier to detach N cells from the culture dishes than S cells, but more difficult to separate the cells from each other.
Results

Morphology of the neuroblastoma cell lines
Expression of signaling molecules in the neuroblastoma cell lines
Our laboratory is interested in various effects of IGF-I in neuroblastoma cells including survival, motility, differentiation and proliferation Meyer and Feldman, 2002; Vincent and Feldman, 2002 ). Previously we have reported that SH-EP cells express IRS-1 and low levels of IGF-IR compared to SH-SY5Y cells, which express higher IGF-IR levels and IRS-2 (Singleton et al., 1996; Meyer et al., 2001) . In this report, we extended this study to compare IGF-I signaling in other neuroblastoma cell lines. First, we examined the expression of IGF-IR. Control cells are serum starved and equal amounts of the whole cell lysates are immunoblotted using anti-IGF-IR antibody (Figure 2a ). N cells (SH-SY5Y, IMR32) express the highest levels of IGF-IR followed by I (SH-IN, SK-N-BE(2)-C) and S cells (SH-EP, SK-N-AS). SH-EP cells express almost undetectable levels of IGF-IR, and SK-N-AS cells express a similar level of IGF-IR to I cell lines. Another S cell line that we tested (SMS-KCNs) also shows minimal IGF-IR expression (data not shown). The major substrates for IGF-IR signaling are Shc and IRS proteins (Pronk et al., 1993; Giorgetti et al., 1994; Myers and White, 1996) . When the cell lysates are immunoblotted for IRS-1, S and I cell lines show high levels of IRS-1 expression (Figure 2b ). N cells, however, display very low levels of IRS-1 expression. In contrast, IRS-2 expression is highest in N cells. S cells express undetectable levels of IRS-2 (Figure 2c ). I cells express both IRS-1 and -2. Shc expression is equal among all the neuroblastoma cell lines tested (Figure 2d) . Two of the major downstream signaling pathways that mediate (De Meyts et al., 1994; Cheatham and Kahn, 1995; Miller et al., 1997; Kim and Feldman, 1998; Kim et al., 1998a) . All the neuroblastoma cell lines we tested express similar levels of Akt and p42/p44 MAPK (Figure 2e and f) .
One of the main differences between N and S cells is their tendency to adhere to substrates (Biedler et al., 1973; Rettig et al., 1987; Ciccarone et al., 1989) . It is well known that integrin-mediated signaling pathways play important roles for cell adhesion and motility (Hood and Cheresh, 2002; Meyer and Feldman, 2002) . We have also reported that IGF-I regulates the phosphorylation of FAK and paxillin, both major signaling molecules for integrins Feldman, 1998, 2002) 
IGF-I induces cellular phosphorylation in neuroblastoma cell lines
We next examined IGF-I-induced changes in protein phosphorylation. For this and the remaining experiments, we focused on differences between N and S cell lines. SH-EP, SK-N-AS, SH-SY5Y and IMR32 cell lines are serum starved for 6 h and treated with 10 nm IGF-I for 0-4 h. Equal amounts of whole cell lysates are immunoblotted with anti-pTyr antibody (Figure 4 ). In N cell lines, we can readily detect a time-dependent tyrosine phosphorylation of IGF-IR b subunit at 97 kDa. Maximum phosphorylation of IGF-IR was observed after approximately 10 min and was maintained for at least 24 h (data not shown; Kim et al., 1997) . Consistent with the low levels of IGF-IR expression, we cannot detect the tyrosine phosphorylation of IGF-IR in S cells. In N cells, IGF-I treatment . These correspond to the known molecular weights of IRS-1 and -2, FAK and p42 and p44 MAPK, which are consistent with our previous reports (Kim et al., , 1998b Kim and Feldman, 2002) .
To analyse the IGF-I-induced changes in IRS more carefully, we first immunoprecipitated IRS-1 and -2 and immunoblotted with anti-pTyr antibody. Even though IGF-IR tyrosine phosphorylation is very low in whole cell lysates with anti-pTyr immunoblotting, IRS-1 is phosphorylated by IGF-I in S cell lines ( Figure 5a , upper panels). IRS-1 phosphorylation starts as early as 5 min and is maintained for at least 4 h. IRS-2 in N cells is also tyrosine phosphorylated by IGF-I within 5 min. However, unlike IRS-1 phosphorylation in S cells, IRS-2 phosphorylation in N cells attenuates after 5 min. The observed time course of IRS-2 phosphorylation correlates with IRS-2 protein levels. IRS proteins can be degraded following insulin or IGF-I treatment by PI 3-K-and proteasome-dependent pathways (Kim et al., 1998b; Haruta et al., 2000; Rui et al., 2001b) . In agreement with these reports, IGF-I treatment induces rapid degradation of IRS-2 in N cell lines (Figure 5a , lower panels). However, IRS-1 protein levels in S cell lines are not affected by IGF-I treatment.
IGF-I treatment also induces strong phosphorylation of p66 and p52 Shc in N cells, which lasts for at least 4 h ( Figure 5b , upper panels). In SK-N-AS cells, IGF-I induces very weak phosphorylation of p52 Shc, and in SH-EP cells p52 phosphorylation is reduced at 4 h by IGF-I treatment. IGF-I treatment does not alter Shc protein levels in all cell lines tested (Figure 5b , lower panels).
We have previously shown that IGF-I treatment results in the activation of Akt and MAPK, which play major roles in IGF-I-mediated neuronal differentiation and survival (Kim et al., , 1998a Russell et al., 1998; Cheng et al., 2000; van Golen et al., 2001) . Akt activation is stronger in N cells, although present in S cells (Figure 5c ). The pattern of MAPK activation is equally different between the two cell types. SH-EP cells show high basal MAPK phosphorylation, which is time dependently decreased by IGF-I treatment (Figure 5c ). MAPK and Akt activations are maintained up to 24 h in N cells (Figure 9 ).
IGF-I-induced membrane ruffling requires PI 3-K activation
We have previously reported that IGF-I treatment in SH-SY5Y cells results in lamellipodial extension and membrane ruffling Kim et al., 1998a) . In this report, we extended our study to compare the morphological changes in S and N cells using SH-EP and IMR32 cells. After serum-starved cells are treated with 10 nm IGF-I, they are incubated with Texas Redconjugated phalloidin to stain actin fibers ( Figure 6 ). Control SH-EP cells show flattened morphology with well-arranged actin stress fibers. In contrast, IMR32 cells show many processes and show little actin stress fibers. At 5 min after IGF-I treatment, both SH-EP and IMR32 cells start to show dense staining of actin filaments at the leading edge of the membrane, which represents membrane ruffling Kim et al., 1998a) . In addition to membrane ruffling, IMR32 cells also display extension of lamellipodia. Both membrane ruffling and lamellipodial extension are most active at 15 min and diminish after 30 min. After 2 h, SH-EP cells return to a shape similar to control cells; however, IMR32 cells begin to show longer neurites, an effect that continues for 24 h (Figure 9) .
In SH-SY5Y cells, IGF-I-induced membrane ruffling requires intact PI 3-K activity (Kim and Feldman, 1998; Kim et al., 1998a) . Therefore, we examined whether the PI 3-K pathway also plays a role in other neuroblastoma cell lines in IGF-I-induced membrane ruffling. In agreement with previous results, IGF-I treatment induces membrane ruffling in SH-EP and IMR 32 cells (Figure 7) . Treatment with PD98059, a specific inhibitor of the MAPK kinase MEK, before IGF-I treatment has no effect on IGF-I-induced membrane ruffling, even though it almost completely blocks MAPK activation (see side panel blot). In contrast, pretreatment of the cells with the PI 3-K inhibitor LY294002, which results in inhibition of Akt activation (see side panel blot), completely blocks IGF-I-induced membrane ruffling in both cell lines. PD98059 and LY294002 have similar effects on SK-N-AS and SH-SY5Y cells (data not shown). These results suggest that the PI 3-K pathway, not MAPK pathway, is required for IGF-I-induced membrane ruffling.
Phosphorylation and localization of FAK and paxillin
FAK and paxillin play important roles in cell morphological changes by connecting integrin signals to the actin cytoskeleton (Schaller, 2001; Parsons, 2003) . Consistent with our previous studies Kim and Feldman, 1998) , IGF-I treatment leads to a slight increase of the tyrosine phosphorylation of FAK shown by immunoblotting with the antibody against pY397 of FAK (Figure 8a) . IGF-I treatment shows stronger responses of paxillin tyrosine phosphorylation (Figure 8a ). To help understand the roles of FAK and paxillin during IGF-I-mediated morphological changes, we studied the localization of these proteins by immunostaining in SH-EP and SH-SY5Y cells. In SH-EP cells, both FAK and paxillin show punctate patterns of staining representing focal adhesion sites, which localize at the tip of the actin stress fibers (Figure 8b) . A 15-min treatment of IGF-I results in redistribution of paxillin more than FAK at the edges of ruffles (Figure 8b) . The staining at the area of ruffling is much smaller than that of the cell body (dot like in the ruffling area compared to streak like in the cell body) and more concentrated. In SH-SY5Y cells, both FAK and paxillin are localized only at the tip of the cells and show little staining at the cell body ( Figure 8c ). In contrast to SH-EP cells, IGF-I treatment results in dramatic changes in FAK and paxillin staining. The cells show numerous punctate staining at the expanding lamellipodial region behind the site of ruffling. There is little staining at the leading membrane edge where membrane ruffling is most active.
Both PI 3-K and MAPK pathways are required for IGF-I-induced neurite outgrowth
We have previously shown that long-term treatment of IGF-I in SH-SY5Y cells results in neurite outgrowth (Kim et al., , 1998b ). Similar to SH-SY5Y cells, 24 h treatment of IGF-I in IMR32 cells also results in neurite outgrowth (Figure 9a and b) . The neurites are 87% (SH-SY5Y) and 66% (IMR32) longer compared to control cells (Figure 9c ). IGF-I does not induce any noticeable long-term morphological changes in S cells (data not shown). When the cell lysates are immunoblotted, we can detect strong phosphorylation of Akt and MAPK after a 24 h IGF-I treatment, which is blocked by simultaneous incubation with the inhibitors. Treatment of the cells with either PD98059 or LY294002 greatly inhibited neurite outgrowth in SH-SY5Y and IMR32 cells. These results suggest that both MAPK and PI 3-K pathways are necessary for IGF-I-induced neurite outgrowth.
DISCUSSION
Neuroblastoma is the most common malignant tumor in children and the present cure rate is very low (Frappaz et al., 2000; Schmidt et al., 2000) . N-myc expression imparts an aggressive tumor phenotype, but occurs in only one-third of aggressive neuroblastoma (Corvi et al., 1997) , suggesting that alternate signaling molecules are important in neuroblastoma tumorigenesis. Growth factors, particularly IGF-I and -II, represent one such class of signaling molecules. IGF-I/II signaling through IGF-IR can modulate neuroblastoma survival, differentiation, proliferation and motility (Singleton et al., 1996; Kim et al., 1997; van Golen and Feldman, 2000; Meyer et al., 2001) . The current study expands on our previous reports by examining IGF-I signaling in specific neuroblastoma cell types. Neuroblastoma tumors consist of a heterogeneous mix of S and N cell types that differ in morphology and aspects of their signaling responses to IGF-I, which may contribute to their tumorigenic capabilities. In the current study, the most prominent differences between N and S cells are the expression levels of IGF-IR and IRS docking proteins. N cells (SH-SY5Y and IMR-32) express a higher level of IGF-IR than S cells (SH-EP and SK-N-AS) and express only IRS-2, while S cells express only IRS-1. Despite the differences in IGF-IR expression levels, IRS-1 and -2 are both tyrosine phosphorylated by IGF-I treatment. These data suggest that the different IRS expression patterns in N and S cells could be as important as the level of IGF-IR expression in determining a cell's phenotype.
The differential roles of IRS proteins in tumorigenesis are supported through work by several laboratories. Valentinis et al. (1999 Valentinis et al. ( , 2000 report that 32D cells transfected with IGF-IR (32D/IGF-IR) differentiate in response to IGF-I, like N cells. However, when 32D/ IGF-IR cells are cotransfected with IRS-1, the cells lose their ability to differentiate and begin to proliferate. In addition, overexpression of IRS-1 increases cell adhesion and decreases cell motility in LNCaP prostatic cancer cells, a phenotype similar to S cells . Collectively, our results and those of others (Valentinis et al., 1999; Reiss et al., 2000; Meyer et al., 2001 ) support a pivotal role for IRS expression in determining different degrees of cancer cell motility and adherence.
Our results suggest that IRS activity is regulated by protein phosphorylation and degradation. Phosphorylation of IRS-2 in N cells is transient compared to the sustained phosphorylation of IRS-1 in S cells. The time course of IRS phosphorylation correlates with IRS expression levels; IRS-2 in N cells is rapidly degraded by IGF-I treatment, whereas the amount of IRS-1 protein in S cells remains stable. Several groups have reported that IRS proteins undergo serine phosphorylationdependent degradation by insulin, IGF-I and TNF treatment (Rui et al., 2001a; Pederson et al., 2001; Greene et al., 2003) . We have also shown that IRS-2 is degraded through PI 3-K signaling in SH-SY5Y cells (Kim et al., 1998b) . Little IRS-1 degradation occurs in S cells after IGF-I treatment, even though IRS-1 is strongly tyrosine phosphorylated. Transfection of the IGF-IR into SH-EP cells results in basal and IGF-Imediated decreases in IRS-1 (data not shown). Therefore, it is possible that higher levels of IGF-IR expression are required to activate the signaling molecules responsible for IRS serine phosphorylation and degradation, such as SOCS (Rui et al., 2001b) . Alternatively, in neuroblastoma IRS-1 and -2 could have inherent different sensitivities for IGF-I-mediated Insulin-like growth factor-I signaling in neuroblastoma B Kim et al phosphorylation and degradation, as has been observed in skeletal muscle cells (Ogihara et al., 1997) . Stimulation of the IGF-IR and recruitment of the adaptor molecules IRS and Shc lead to the activation of the PI 3-K and MAPK signaling pathways (Myers and White, 1996; Waters and Pessin, 1996) . Even though IRS-1 and -2 are strongly tyrosine phosphorylated, regardless of the expression level of IGF-IR, Shc phosphorylation is dependent on the IGF-IR level. p66 and p52 Shc are strongly phosphorylated in N cells by IGF-I, but are very weakly phosphorylated in one S cell line, SK-N-AS. Whereas Akt is exclusively activated by the PI 3-K pathway and is dependent on IRS protein activation (Franke et al., 1997) , MAPK activation through Grb2/SOS-Ras can occur by either IRS or Shc signaling (Baltensperger et al., 1993; Sasaoka et al., 1994) . We have previously suggested that Shc, rather than IRS-2, plays a major role in the activation of MAPK in SH-SY5Y cells (Kim et al., 1998a) . The current results again support the contention that Shc, not IRS, is the major IGF-IR docking molecule for downstream activation of MAPK. First, even though IRS-1 is strongly tyrosine phosphorylated by IGF-I in S cells, MAPK is very weakly phosphorylated or dephosphorylated in these same cell lines. Second, in N cells, IRS-2 phosphorylations is transient, whereas Shc and MAPK phosphorylations show sustained activation up to 24 h. Therefore, IGF-IR activation of Shc for MAPK signaling and IRS proteins for PI 3-K activity may provide a way for distinct IGF-mediated events in neuroblastoma (Kim et al., 1998a) .
A separate IGF-mediated event that requires both PI 3-K and MAPK activity is neurite outgrowth. Our previous report that IGF-I mediates neurite outgrowth in N cells has been corroborated by other groups (Encinas et al., 1999; Seiler et al., 2001) . Neurite outgrowth is one marker of N cell differentiation and corresponds with the expression of specific differentiation markers . Results from the current study suggest that IGF-I activation of both Insulin-like growth factor-I signaling in neuroblastoma B Kim et al PI 3-K and MAPK pathways is needed for IGF-Imediated neurite outgrowth in N cells. In agreement with our results, Kurihara et al. (2000) reported that inhibition of either MAPK or PI 3-K pathways results in decreased neurite outgrowth, while Sarbassov and Peterson (1998) found that PI 3-K is required for the prolonged activation of MAPK in myogenic differentiation.
Other important components of tumorigenesis, including tumor attachment and migration, are regulated by differential expression of integrin b subunits (Schaller, 2001; Hood and Cheresh, 2002) . The expression of b1 integrin correlates with attached, adherent cells, while the absence of this integrin promotes detachment and rounding of cells (Judware and Culp, 1995; Guo et al., 2002) . In the current study, N cells expressed low levels of b1 integrin, while S cell expression was high. Our data agree with observations made in primary neuroblastoma tumors, where b1 integrin heterodimers are expressed at very low levels in aggressive neuroblastic N cells (Yoshihara et al., 1992) . The expression of b1 is present in tumors with good prognosis (Favrot et al., 1991) , but absent in N-Myc-positive tumors with a poor prognosis (Favrot et al., 1991) . Transfection and overexpression of N-Myc in neuroblastoma cell lines led to an aggressive phenotype and a relative loss of b1 integrin expression (Flickinger et al., 1994; Judware and Culp, 1995) . Collectively, these reports support our hypothesis that decreased b1 integrin expression promotes the nonadherent, motile phenotype in N cells, while increased expression corresponds with the adherent, flattened S cell phenotype.
As the cytoplasmic tails of integrin b subunits are short with no endogenous enzymatic activity, adaptor proteins are necessary to link integrin heterodimers to intracellular signaling pathways (Giancotti and Ruoslahti, 1999) . FAK, an integrin adaptor protein crucial for focal adhesion formation and tumor migration (Sieg et al., 2000) , is activated by growth factors, including IGF-I, in several neuroblastoma cell lines Feldman, 1998, 2002) , suggesting that FAK could promote signaling crosstalk between integrin receptors and IGF-IR in neuroblastoma (Meyer and Feldman, 2002) . Paxillin, a downstream target of FAK, is tyrosine phosphorylated by direct binding through its LD motifs (Bellis et al., 1995; Thomas et al., 1999) and mediates reorganization of the actin cytoskeleton (Schaller, 2001 ). FAK expression is relatively uniform among N and S cells. In contrast, paxillin expression is significantly decreased in N cells compared to S cells, suggesting that paxillin expression may be important in determining tumor phenotype. Reports from other cancer cell lines show that invasive nonadherent tumors express reduced levels of paxillin (Scibelli et al., 2003) , while overexpression of paxillin results in decreased motility and tumorigenesis .
In the current study, FAK and paxillin are tyrosine phosphorylated by IGF-I in S and N cells. In both S and N cells, FAK and paxillin show sustained phosphorylation at least up to 4 h. FAK is known to be a direct substrate of IRS-1 (Lebrun et al., 1998) In S cells, prior to IGF-I treatment, both FAK and paxillin are localized to the ends of actin stress fibers and evenly spread throughout the cytoplasm. While IGF-I treatment for 15 min has little effect on FAK localization, paxillin is localized to membrane ruffles. This may be related to the greater phosphorylation responsiveness of paxillin compared to FAK, suggesting a more important role for paxillin than FAK in the actin cytoskeleton changes in S cells. In untreated N cells both FAK and paxillin are localized only at the cell periphery. The distribution of FAK and paxillin and the lack of actin stress fibers in N cells suggest that these cells, unlike S cells, attach to the substrate only at cellular edges, which explain the loose adherence of N cells to substrates. In agreement with previous studies , IGF-I treatment results in active relocalization of FAK and paxillin to the lamellipodial area of N cells. The different distribution of FAK and paxillin in S and N cells suggests that these signaling molecules play distinct roles in IGF-I-mediated cytoskeletal changes.
In summary, N and S cells differ in their expression and activation of IGF-IR and IRS isoforms, leading to differences in downstream signaling and morphological changes in response to IGF treatment. These differences in IGF-I-mediated signaling define in part the 'biochemical fingerprint' of neuroblastoma cells. Future work to characterize the properties and manipulate the expression and activation of the IGF-IR further, IRS isoforms, Shc, FAK and paxillin may lead to a better understanding of what roles the cell-type-specific differences in signaling mechanisms play in the development of a tumorigenic phenotype in neuroblastoma cells.
Experimental procedures
Materials
Anti-IGF-IR, anti-IRS-1 and -2, anti-actin antibodies, secondary antibodies for Western immunoblotting and protein A/G-agarose beads were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against phosphorylated and regular Akt and MAPK were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-Shc, anti-FAK, anti-paxillin and anti-b1 integrin antibodies were obtained from Transduction Laboratories (Lexington, KY, USA). Antibodis against phosphorylated Shc (pY239/pY240), FAK (pY397) and paxillin (pY118) were obtained from Biosource International (Camarillo, CA, USA). Antiphosphotyrosine (pTyr) antibody (4G10) was obtained from Upstate Biotechnology (Lake Placid, NY, USA). Texas Red-conjugated phalloidin, biotin-labeled secondary antibodies and fluorescein isothiocyanate (FITC)-labeled avidin were obtained from Vector Laboratories (Burlingame, CA, USA). PD98050 and LY294002 were purchased from Calbiochem (La Jolla, CA, USA). Recombinant human IGF-I was kindly provided by Cephalon, Inc. (Westchester, PA, USA).
Cell culture
SH-EP, SK-N-AS, SH-SY5Y and IMR32 human neuroblastoma cells were maintained in DMEM containing 10% calf serum. SH-IN and SK-N-BE(2)-C cells were kindly provided by Dr ValerieCastle of the University of Michigan and maintained in MEM/F-12 (1 : 1) containing 10% fetal calf serum and antibiotics. The cells were serum starved for 4-6 h before each experiment. For neurite outgrowth experiments, the cells were treated with IGF-I7inhibitors for 24 h. The neurite length was measured using Scion Image software.
Immunoblotting, immunoprecipitation and immunocytochemistry
Immunoblotting and immunoprecipitation were performed as previously described . All the experiments were repeated at least three times and the typical representative results are presented in the figures. Immunocytochemistry was performed as described previously .
